Results 71 to 80 of about 18,371 (263)

Cisterna Chyli Dilation Is a Risk Factor for Liver Nodules and Hepatocellular Carcinoma in Fontan‐Associated Liver Disease: Pathophysiological Role of Lymphatic Dysfunction

open access: yesHepatology Research, EarlyView.
ABSTRACT Aim In Fontan‐associated liver disease (FALD), chronic congestion often confounds conventional fibrosis markers, complicating surveillance for hepatocellular carcinoma (HCC). Although lymphatic dysfunction is fundamental to Fontan physiology, its contribution to hepatocarcinogenesis remains unclear.
Koji Imoto   +14 more
wiley   +1 more source

Refractory IgG4-related Pleural Disease with Chylothorax: A Case Report and Literature Review

open access: yesInternal medicine, 2021
We herein report a rare case of a 66-year-old man with refractory chylothorax. Although he had been treated with moderate doses of prednisolone (PSL) on suspicion of pleuritis with Sjögren syndrome, the pleural effusion expanded after the reduction of ...
K. Sakata   +10 more
semanticscholar   +1 more source

How efficacious are Octreotide and Somatostatin in the management of chylothorax in congenital cardiac surgical patients?

open access: yesInteractive Cardiovascular and Thoracic Surgery, 2021
A best evidence topic in cardiac surgery was written according to a structured protocol. The question addressed was how efficacious are Octreotide and Somatostatin in the management of chylothorax in congenital cardiac surgical patients.
Sudharsan Madhavan, M. Nakao
semanticscholar   +1 more source

Presentations and management of different causes of chylothorax in children: one medical center’s experience

open access: yesBioMedicine, 2017
Background: Chylothorax in children is a relatively rare cause of pleural effusion. However, it is usually a common complication of cardiothoracic operations like open-heart surgery.
Lin Chien-Heng   +2 more
doaj   +1 more source

A transudative chylothorax associated with superior vena cava syndrome

open access: yesRespiratory Medicine Case Reports, 2019
The chylothorax is a lymphocyte predominant protein-discordant exudative pleural effusions with low lactate dehydrogenase and elevated triglyceride levels.
Adam Austin   +3 more
doaj   +1 more source

Transudative chylothorax in liver cirrhosis; an underappreciated entity

open access: yesRespiratory Medicine Case Reports, 2020
Chylothorax is a rare pathology with potentially severe consequences. Transudative chylothorax remain an extremely rare entity. Cirrhosis is often an underappreciated cause. We report a case of transudative chylothorax in 62-year-old woman with cirrhosis
Asma Migaou   +9 more
doaj   +1 more source

Double trouble: Biochemically confirmed bilateral chylothorax with positive pleural fluid cytology due to breast adenocarcinoma

open access: yesRespiratory Medicine Case Reports, 2022
Although chylothorax is a well-described complication of malignancy, especially lymphoma, breast adenocarcinoma has not been a commonly implicated primary tumor. There has been only one published report of biochemically confirmed bilateral chylothorax in
Ralph Llewel Sabang   +4 more
doaj   +1 more source

Toxicity of Cytarabine Intravenous Constant Rate Infusion in Cats With Lymphoma

open access: yesVeterinary and Comparative Oncology, EarlyView.
ABSTRACT Cytarabine intravenous constant rate infusion (IV CRI) toxicity in cats with lymphoma has not been well documented. We aimed to assess toxicities following cytarabine IV CRI as a single‐agent or within a multiagent protocol in cats with lymphoma. Medical records of cats with lymphoma treated with cytarabine IV CRI, with documented dose, route,
Rachel Hanford   +5 more
wiley   +1 more source

PANORAMIC AITIA IN CHYLOTHORAX [PDF]

open access: yes
The etiology of chylothorax can be divided into a)Traumatic b)Spontaneous and c)Idiopathic. Traumatic chylothorax, usually following iatrogenic injury like oesophageal surgery accounts for0.3-5%.
Elilnambi Sundaramoorthy, Kathirvel
core   +1 more source

Safety and Effectiveness of a High‐Dose, Tailored Tissue Plasminogen Activator Therapy Protocol: A Joint Pediatric Hematology and Cardiac ICU Quality Improvement Initiative Analysis

open access: yesPediatric Blood &Cancer, Volume 73, Issue 11, November 2026.
ABSTRACT Background Pediatric thromboembolism is increasingly encountered in critical care. Systemic thrombolysis with tissue plasminogen activator (tPA) facilitates vessel or valve patency, yet pediatric‐specific protocols remain undefined, and safety concerns persist. Objective To evaluate the efficacy and safety of a tailored, prolonged systemic tPA
Eran Shostak   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy